STOCK TITAN
  1. Home
  2. Sec-filings
  3. WVE
  4. [Form 3] Wave Life Sciences Ltd. Initial Statement of Beneficial Ownership

Wave Life Sciences (WVE) CSO details options, RSUs and share stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Wave Life Sciences Ltd. Chief Scientific Officer Erik Ingelsson filed an initial ownership report showing his current equity position in the company. He directly holds 87,864 ordinary shares, including 17,489 shares and time-based RSUs that vest in annual installments from February 8, 2027 through February 8, 2030, subject to his continued service.

Ingelsson also holds three option awards to purchase ordinary shares: 350,000 shares at an exercise price of $5.85 expiring on May 8, 2034; 200,000 shares at $11.74 expiring on February 4, 2035; and 273,750 shares at $12.75 expiring on February 5, 2036. Each option vests over several years, with 25% vesting on an initial date and the remainder vesting quarterly, conditioned on continued service.

Positive

  • None.

Negative

  • None.
Insider Ingelsson Erik
Role Chief Scientific Officer
Type Security Shares Price Value
holding Share Option (Right to Buy) -- -- --
holding Share Option (Right to Buy) -- -- --
holding Share Option (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Share Option (Right to Buy) — 350,000 shares (Direct); Ordinary Shares — 87,864 shares (Direct)
Footnotes (1)
  1. Consists of (i) 17,489 ordinary shares, (ii) 24,750 RSUs that vest in three equal annual installments on February 8, 2027 through February 8, 2029; and (iii) 45,625 RSUs that vest in four equal annual installments of 25% beginning on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date. The option vested as to 25% of the shares on May 8, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until May 8, 2028, subject to the Reporting Person's continued service through the applicable vesting date. The option vested as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029, subject to the Reporting Person's continued service through the applicable vesting date. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
Direct ordinary shares 87,864 shares Total ordinary shares directly held following Form 3
Current ordinary shares 17,489 shares Component of direct holdings noted in footnote
RSUs vesting 2027–2029 24,750 RSUs Vest in three equal annual installments from Feb 8, 2027–2029
RSUs vesting 2027–2030 45,625 RSUs Vest in four equal annual installments from Feb 8, 2027–2030
Option at $5.85 350,000 shares Share option, exercise price $5.85, expires May 8, 2034
Option at $11.74 200,000 shares Share option, exercise price $11.74, expires Feb 4, 2035
Option at $12.75 273,750 shares Share option, exercise price $12.75, expires Feb 5, 2036
Share Option (Right to Buy) financial
"security_title: "Share Option (Right to Buy)""
RSUs financial
"24,750 RSUs that vest in three equal annual installments"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Ordinary Shares financial
"underlying_security_title: "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
vesting financial
"RSUs that vest in three equal annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Chief Scientific Officer financial
"officer_title: "Chief Scientific Officer""
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Ingelsson Erik
(Last)(First)(Middle)
C/O WAVE LIFE SCIENCES LTD.,
733 CONCORD AVE.
(Street)
CAMBRIDGE MASSACHUSETTS 02138
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
04/09/2026		3. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares87,864(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy) (2)05/08/2034Ordinary Shares350,000$5.85D
Share Option (Right to Buy) (3)02/04/2035Ordinary Shares200,000$11.74D
Share Option (Right to Buy) (4)02/05/2036Ordinary Shares273,750$12.75D
Explanation of Responses:
1. Consists of (i) 17,489 ordinary shares, (ii) 24,750 RSUs that vest in three equal annual installments on February 8, 2027 through February 8, 2029; and (iii) 45,625 RSUs that vest in four equal annual installments of 25% beginning on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
2. The option vested as to 25% of the shares on May 8, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until May 8, 2028, subject to the Reporting Person's continued service through the applicable vesting date.
3. The option vested as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029, subject to the Reporting Person's continued service through the applicable vesting date.
4. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
Remarks:
Exhibit 24.1 - Power of Attorney
/s/ Erik Ingelsson04/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Wave Life Sciences (WVE) Form 3 report for Erik Ingelsson?

The Form 3 shows Chief Scientific Officer Erik Ingelsson’s initial ownership in Wave Life Sciences, including 87,864 ordinary shares, multiple RSU awards vesting through 2030, and several stock option grants with exercise prices between $5.85 and $12.75 per share.

How many ordinary shares of WVE does Erik Ingelsson hold directly?

Erik Ingelsson directly holds 87,864 ordinary shares of Wave Life Sciences. This figure combines 17,489 currently held shares with RSUs scheduled to vest in equal annual installments between February 8, 2027 and February 8, 2030, subject to continued service.

What stock options does the WVE Chief Scientific Officer hold?

He holds three option grants to buy Wave Life Sciences ordinary shares: 350,000 shares at $5.85 expiring May 8, 2034; 200,000 shares at $11.74 expiring February 4, 2035; and 273,750 shares at $12.75 expiring February 5, 2036, all vesting over multiple years.

How do Erik Ingelsson’s RSUs at Wave Life Sciences vest?

He has 24,750 RSUs vesting in three equal annual installments on February 8, 2027–2029, and 45,625 RSUs vesting in four equal annual installments starting February 8, 2027 through February 8, 2030. Vesting depends on his continued service with the company.

Are there any recent insider share purchases or sales by WVE’s CSO in this filing?

This Form 3 does not disclose new purchases or sales. It is an initial ownership filing listing Erik Ingelsson’s existing ordinary shares, RSU awards, and stock options, rather than reporting new open-market transactions or option exercises.